Kerry Group (KRZ) Investor Day 2026 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2026 summary
9 Oct, 2026Strategic position and growth
Portfolio transformation completed just under two years ago, creating a pure-play B2B taste and nutrition business; biotechnology, global footprint and retailer go-to-market capabilities expanded.
Strategy prioritizes volume growth, EBITDA margin expansion, EPS, cash flow and returns, with innovation and renovation supported by technology, application expertise and integrated solutions.
Accelerate 2.0 optimizes the footprint and scales digital initiatives across commercial, R&D, supply chain, manufacturing and business functions.
Market opportunity and customer dynamics
Addressable value-add specialty ingredient market is €87bn and projected to exceed €100bn in 5-10 years, primarily driven by renovation.
Inflation, affordability pressures, regulation, health and wellness trends and supply-chain disruption prompt reformulation, while customers seek to protect product quality and taste.
Customer demand is shifting toward integrated outcomes spanning consumer appeal, labeling, manufacturing and economics; rapid commercialization is increasingly important.
FY2025 revenue mix: Americas 55%, APMEA 24%, Europe 21%; food 66%, beverage 27%, pharma and other 7%; developed markets 67%, emerging markets 33%.
Technology, R&D and innovation
More than €3bn invested in the science and technology ecosystem over 10 years; 2025 R&D investment was €315m, supporting 1,300+ scientists, 60+ innovation centres, ~400 PhDs and master’s graduates, and 1,200+ patents and applications.
R&D investment target is 5-6% of revenue; digital and AI are being applied to commercial, formulation and analytical knowledge.
Capabilities combine taste technologies, biotechnology, application expertise and customised solutions; 40% of the taste portfolio is delivered through biotechnology.
Five future technology areas each offer potential above €50m: advanced nutrition modulation, fermentation and natural ingredients, resource scarcity solutions, future-proof preservation, and food as a therapeutic.
Solutions include sodium and sugar reduction, masking, clean-label and sorbate-free preservation, natural colours, and fermentation-based taste.
Latest events from Kerry Group
- Q3 volume growth accelerated to 4.1%, with 50 bps margin expansion and EPS guidance maintained.KRZ
Q3 2026 - Margin expansion and strong cash flow offset weaker reported revenue; FY 2024 EPS growth guidance is 5%–8%.KRZ
Q4 2023 - Global taste and nutrition leader driving growth through innovation and sustainability.KRZ
Investor presentation - Driving sustainable growth in taste and nutrition with innovation and strong ESG performance.KRZ
Investor presentation - Strong global growth, innovation, and sustainability drive robust financial performance.KRZ
Corporate presentation - 2030 targets: 3%-5% volume growth, 20%-21% EBITDA margin, and major ESG progress.KRZ
Status update - EBITDA margin rose to 16.7% on 3.3% volume growth, with ambitious 2030 targets set.KRZ
Q2 2026 & Status update - EBITDA margin rose to 16.7% on 3.3% volume growth, with strong cash flow and upgraded 2030 targets.KRZ
Q2 2026 Pre recorded - Margin expansion to 19–20% by 2026, led by innovation, high-growth channels, and a €300m buyback.KRZ
Investor Day 2024